Conducting retrospective impact analysis to inform a medical research charity's funding strategies: The case of Asthma UK

Allergy, Asthma and Clinical Immunology

Volumn 9, Issue 1, 2013, Pages

  Hanney, Stephen R ^a   Watt, Amanda ^b   Jones, Teresa H ^a   Metcalf, Leanne ^c  

^a BRUNEL UNIVERSITY   (United Kingdom)

^b RAND CORPORATION   (United States)

^c ASTHMA UK   (United Kingdom)

Author keywords

Asthma; Asthma UK; Clinical guidelines; Immunotherapy; Payback Framework; Product development; Research funding strategy; Research impacts; Societal impacts; University spin out companies

Indexed keywords

BETA INTERFERON; EOTAXIN; GLUCOCORTICOID; INTERLEUKIN 10;

ARTICLE; ASTHMA; COMMON COLD; DISEASE EXACERBATION; FUNDING; HEALTH ECONOMICS; HUMAN; IMMUNOTHERAPY; KNOWLEDGE; MAJOR CLINICAL STUDY; MEDICAL EDUCATION; MEDICAL RESEARCH; PEER REVIEW; PRACTICE GUIDELINE; PRODUCT DEVELOPMENT; RETROSPECTIVE STUDY; SOCIAL WELFARE; STRUCTURED INTERVIEW;

EID: 84877954110     PISSN: 17101484     EISSN: 17101492     Source Type: Journal    
DOI: 10.1186/1710-1492-9-17     Document Type: Article

References (45)

1. Editorial Unknown quantities. Nature 2010, 465:665-666. Editorial.
2. UK Evaluation Forum Medical research: assessing the benefits to society 2006, London: Academy of Medical Sciences, UK Evaluation Forum.
3. Smith R. Measuring the social impact of research. BMJ 2001, 323:528. 10.1136/bmj.323.7312.528, 1121118, 11546684.
4. Pang T, Terry RF, The PloS Medicine editors WHO/PloS collection " No health without research" : a call for papers. PloS Medicine 2011, 8:1. The PloS Medicine editors.
5. Hanney S, Grant J, Wooding S, Buxton M. Proposed methods for reviewing the outcomes of health research: the impact of funding by the UK's 'Arthritis Research Campaign'. Health Res Policy Syst 2004, 2:4. 10.1186/1478-4505-2-4, 503400, 15272939.
6. Lee TH, Barnes J. Where next in basic allergy?. Clin Exp Allergy 2002, 32:499-506. 10.1046/j.0954-7894.2002.01367.x, 11972593.
7. Buxton M, Hanney S, Morris S, Sundmacher L, Mestre-Ferrandiz J, Garau M, Sussex J, Grant J, Ismail S, Nason E, Wooding S. Medical research - What's it worth? estimating the economic benefits from medical research in the UK 2008, London: UK Evaluation Forum (Academy of Medical Sciences, MRC, Wellcome Trust).
8. Hanney S, Buxton M, Green C, Coulson D, Raftery J. An assessment of the impact of the NHS health technology assessment programme. Health Technol Assess 2007, 11:53.
9. Canadian Academy of Medical Sciences Making an impact: a preferred framework and indicators to measure returns on investment in health research 2009, Ottowa: Canadian Academy of Medical Sciences, Canadian Academy of Medical Sciences.
10. Banzi R, Moja L, Pistotti V, Facchini A, Liberati A. Conceptual frameworks and empirical approaches used to assess the impact of health research: an overview of reviews. Health Res Policy Syst 2011, 9:26. 10.1186/1478-4505-9-26, 3141787, 21702930.
11. Buxton M, Hanney S. How can payback from health services research be assessed?. J Health Serv Res Policy 1996, 1:35-43.
12. Wooding S, Hanney S, Buxton M, Grant J. Payback arising from research funding: evaluation of the arthritis research campaign. Rheumatology (Oxford) 2005, 44:1145-1156.
13. Oortwijn WJ, Hanney SR, Ligtvoet A, Hoorens S, Wooding S, Grant J, Buxton M, Bouter L. Assessing the impact of health technology assessment in The Netherlands. Int J Technol Assess Health Care 2008, 24:259-269.
14. Hanney S, Gonzalez-Block M, Buxton M, Kogan M. The utilisation of health research in policy-making: concepts, examples and methods of assessment. Health Res Policy Syst 2003, 1:2. 10.1186/1478-4505-1-2, 151555, 12646071.
15. Jose PJ, Griffiths-Johnson DA, Collins PD, Walsh DT, Moqbel R, Totty NF, Truong O, Hsuan JJ, Williams TJ. Eotaxin: a potent eosinophil chemoattractant cytokine detected in a guinea-pig model of allergic airways inflammation. J Exp Med 1994, 179:881-887. 10.1084/jem.179.3.881, 2191401, 7509365.
16. Christie PE, Tagari P, Ford-Hutchinson AW, Charlesson S, Chee P, Arm JP, Lee TH. Urinary leukotriene-e4 concentrations increase after aspirin challenge in aspirin-sensitive asthmatic subjects. Am Rev Respir Dis 1991, 143:1025-1029. 10.1164/ajrccm/143.5_Pt_1.1025, 1850964.
17. Durham SR, Walker SM, Varga EM, Jacobson MR, O'Brien F, Noble W, Till SJ, Hamid QA, Nouria-Aria KT. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 1999, 341:468-475. 10.1056/NEJM199908123410702, 10441602.
18. Oldfield WL, Larche M, Kay AB. Effect of T-cell peptides derived from Fel d 1 on allergic reactions and cytokine production in patients sensitive to cats: a randomised controlled trial. Lancet 2002, 360:47-53. 10.1016/S0140-6736(02)09332-7, 12114041.
19. Asthma UK. Asthma UK says farewell to world-leading professor http://www.asthma.org.uk/news-centre/latest-news/2012/01/asthma-uk-says-farewell-to-world-leading-professor.
20. Thomas M, McKinley RK, Mellor S, Watkin G, Holloway E, Scullion J, Shaw DE, Warlaw A, Price D, Pavord I. Breathing exercises for asthma: a randomised controlled trial. Thorax 2009, 64:55-61.
21. Bott J, Blumenthal S, Buxton M, Ellum S, Falconer C, Garrod R. Guidelines for the physiotherapy management of the adult, medical, spontaneously breathing patient. Thorax 2009, 64(Suppl 1):i1-i51. 10.1136/thx.2008.110726, 19406863.
22. Scadding GK, Durham SR, Mirakian R, Jones NS, Leech SC, Farooque S. BSACI guidelines for the management of allergic and non-allergic rhinitis. Clin Exp Allergy 2008, 38:19-42.
23. Bacharier LB, Boner A, Carlsen KH, Eigenmann PA, Frischer T, Gotz M, Helms PJ, Hunt J, Liu A, Papadopoulos N, Platts-Mills T, Pohunek P, Simons FER, Valovirta E, Wahn U, Wildhaber J, The European Pediatric Asthma Group Diagnosis and treatment of asthma in childhood: a PRACTALL consensus report. Allergy 2008, 63:5-34. 10.1111/j.1398-9995.2008.01640.x, 18339040, The European Pediatric Asthma Group.
24. Dicpinigaitis PV. Chronic cough due to asthma: ACCP evidence-based clinical practice guidelines. Chest 2006, 129(1 Suppl):75S-79S.
25. Brightling CE, Bradding P, Symon FA, Holgate ST, Wardlaw AJ, Pavord ID. Mast-cell infiltration of airway smooth muscle in asthma. N Engl J Med 2002, 346:1699-1705. 10.1056/NEJMoa012705, 12037149.
26. British Thoracic Society Scottish Intercollegiate Guidelines Network British guideline on the management of asthma 2008, England, http://www.brit-thoracic.org.uk/Portals/0/Guidelines/AsthmaGuidelines/PreviousAsthmaGuidelines/asthma_final2008.pdf, British Thoracic Society Scottish Intercollegiate Guidelines Network.
27. Saglani S, Nicholson AG, Scallan M, Balfour-Lynn I, Rosenthal M, Payne DN, Bush A. Investigation of young children with severe recurrent wheeze: any clinical benefit?. Eur Respir J 2006, 27:29-35. 10.1183/09031936.06.00030605, 16387932.
28. Berry MA, Shaw DE, Green RH, Brightling CE, Wardlaw AJ, Pavord ID. The use of exhaled nitric oxide concentration to identify eosinophilic airway inflammation: an observational study in adults with asthma. Clin Exp Allergy 2005, 35:1175-1179. 10.1111/j.1365-2222.2005.02314.x, 16164444.
29. Jadad AR, Sigouin C, Mohide PT, Levine M, Fuentes M. Risk of congenital malformations associated with treatment of asthma during early pregnancy. Lancet 2000, 355:119. 10.1016/S0140-6736(99)02542-8, 10675175.
30. Tata LJ, Lewis SA, McKeever TM, Smith CJ, Doyle P, Smeeth L, Gibson JE, Hubbard RH. Effect of maternal asthma, exacerbations and asthma medication use on congenital malformations in offspring: a UK population-based study. Thorax 2008, 63:981-987. 10.1136/thx.2008.098244, 18678701.
31. British Thoracic Society and Scottish Intercollegiate Guidelines Network British Guideline on the Management of Asthma: a national clinical guideline. May 2008. Revised June 2009 http://www.brit-thoracic.org.uk/Portals/0/Guidelines/AsthmaGuidelines/sign101%20revised%20June%2009.pdf, British Thoracic Society and Scottish Intercollegiate Guidelines Network.
32. Xystrakis E, Kusumakar S, Boswell S, Peek E, Urry Z, Richards DF, Adikibi T, Pridgeon C, Dallman M, Loke TK, Robinson DS, Barrat FJ, O'Garra A, Lavender P, Lee TH, Corrigan C, Hawrylowicz CM. Reversing the defective induction of IL-10-secreting regulatory T cells in glucocorticoid-resistant asthma patients. J Clin Invest 2006, 116:146-155. 1307558, 16341266.
33. Christie PE, Smith CM, Lee TH. The potent and selective sulfidopeptide leukotriene antagonist, SK&F 104353, inhibits aspirin-induced asthma. Am Rev Respir Dis 1991, 144:957-958. 10.1164/ajrccm/144.4.957, 1928974.
34. Laitinen LA, Laitinen A, Haahtela T, Vikka V, Spur BW, Lee TH. Leukotriene E and granulocytic infiltration into asthmatic airways. The Lancet 1993, 341:989-990.
35. Wark PA, Johnston SL, Bucchieri F, Powell R, Puddicombe S, Laza-Stanca V, Holgate ST, Davies DE. Asthmatic bronchial epithelial cells have a deficient innate immune response to infection with rhinovirus. J Exp Med 2005, 201:937-947. 10.1084/jem.20041901, 2213100, 15781584.
36. Synairgen IFNβ in Asthma http://www.synairgen.com/programmes/ifn-β-in-asthma.aspx, Synairgen.
37. O'Byrne PM, Gauvreau GM, Murphy DM. Efficacy of leukotriene receptor antagonists and synthesis inhibitors in asthma. J Allergy Clin Immunol 2009, 124:397-403. 10.1016/j.jaci.2009.05.029, 19608262.
38. Walker S, Khan-Wasti S, Fletcher M, Cullinan P, Harris J, Sheikh A. Seasonal allergic rhinitis is associated with a detrimental effect on examination performance in united kingdom teenagers: case-controlled study. J Allergy Clin Immunol 2007, 120:381-387. 10.1016/j.jaci.2007.03.034, 17560637.
39. House of Lords Science and Technology Committee Allergy. Volume 1: Report. HL Paper 166-1 2007, London: The Stationery Office, House of Lords Science and Technology Committee.
40. Cooksey D. A review of UK health research funding 2006, London: HM Treasury.
41. Hanney S, Kuruvilla S, Soper B, Mays N. Who needs what from a national health research system: lessons from reforms to the English department of Health's R&D system. Health Res Policy Syst 2010, 8:11. 10.1186/1478-4505-8-11, 2881918, 20465789.
42. National Institute for Health Research Delivering health research: national institute for health research progress report 2008/9 2009, London: Department of Health, National Institute for Health Research.
43. Synairgen Positive Phase II asthma clinical trial data http://www.synairgen.com/media/1536/19%20april%202012%20Phase%20II%20press%20release%20final.pdf, Synairgen.
44. Nason E, Curran B, Hanney S, Janta B, Hastings G, O'Driscoll M, Wooding S. Evaluating health research funding in Ireland: assessing the impacts of the Health Research Board of Ireland's funding activities. Res Eval 2011, 20:193-200.
45. Adam P, Solans-Domènech M, Pons JMV, Aymerich M, Berra S, Guillamon I, Sánchez E, Permanyer-Miralda G. Assessment of the impact of a clinical and health services research call in Catalonia. Res Eval 2012, 21:319-328.